A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors

Emicizumab, a bispecific humanized monoclonal antibody, bridges activated factor IX (FIX) and FX to restore the function of missing activated FVIII in hemophilia A. Emicizumab prophylaxis in children with hemophilia A and FVIII inhibitors was investigated in a phase 3 trial (HAVEN 2). Participants,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Young, Guy, Liesner, Ri, Chang, Tiffany, Sidonio, Robert, Oldenburg, Johannes, Jiménez-Yuste, Victor, Mahlangu, Johnny, Kruse-Jarres, Rebecca, Wang, Michael, Uguen, Marianne, Doral, Michelle Y., Wright, Lilyan Y., Schmitt, Christophe, Levy, Gallia G., Shima, Midori, Mancuso, Maria Elisa
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2019
Assuntos:
Plenary Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6908828/
https://ncbi.nlm.nih.gov/pubmed/31697801
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019001869
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados